LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 16

Search options

  1. Article: Ferroptosis: A Specific Vulnerability of RAS-Driven Cancers?

    Andreani, Cristina / Bartolacci, Caterina / Scaglioni, Pier Paolo

    Frontiers in oncology

    2022  Volume 12, Page(s) 923915

    Abstract: Ferroptosis has emerged as a new type of programmed cell death that can be harnessed for cancer therapy. The concept of ferroptosis was for the first time proposed in in the early 2000s, as an iron-dependent mode of regulated cell death caused by ... ...

    Abstract Ferroptosis has emerged as a new type of programmed cell death that can be harnessed for cancer therapy. The concept of ferroptosis was for the first time proposed in in the early 2000s, as an iron-dependent mode of regulated cell death caused by unrestricted lipid peroxidation (LPO) and subsequent plasma membrane rupture. Since the discovery and characterization of ferroptosis, a wealth of research has improved our understanding of the main pathways regulating this process, leading to both the repurposing and the development of small molecules. However, ferroptosis is still little understood and several aspects remain to be investigated. For instance, it is unclear whether specific oncogenes, cells of origin or tumor niches impose specific susceptibility/resistance to ferroptosis or if there are some ferroptosis-related genes that may be used as
    Language English
    Publishing date 2022-07-15
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2649216-7
    ISSN 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2022.923915
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Lipid Metabolism Regulates Oxidative Stress and Ferroptosis in RAS-Driven Cancers: A Perspective on Cancer Progression and Therapy.

    Bartolacci, Caterina / Andreani, Cristina / El-Gammal, Yasmin / Scaglioni, Pier Paolo

    Frontiers in molecular biosciences

    2021  Volume 8, Page(s) 706650

    Abstract: ... ...

    Abstract HRAS
    Language English
    Publishing date 2021-08-16
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2814330-9
    ISSN 2296-889X
    ISSN 2296-889X
    DOI 10.3389/fmolb.2021.706650
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: SIRT6 promotes metastasis and relapse in HER2-positive breast cancer.

    Andreani, Cristina / Bartolacci, Caterina / Persico, Giuseppe / Casciaro, Francesca / Amatori, Stefano / Fanelli, Mirco / Giorgio, Marco / Galié, Mirco / Tomassoni, Daniele / Wang, Junbiao / Zhang, Xiaoting / Bick, Gregory / Coppari, Roberto / Marchini, Cristina / Amici, Augusto

    Scientific reports

    2023  Volume 13, Issue 1, Page(s) 22000

    Abstract: The histone deacetylase sirtuin 6 (SIRT6) has been endowed with anti-cancer capabilities in many tumor types. Here, we investigate the impact of SIRT6-overexpression (SIRT6-OE) in Delta16HER2 mice, which are a bona fide model of HER2-positive breast ... ...

    Abstract The histone deacetylase sirtuin 6 (SIRT6) has been endowed with anti-cancer capabilities in many tumor types. Here, we investigate the impact of SIRT6-overexpression (SIRT6-OE) in Delta16HER2 mice, which are a bona fide model of HER2-positive breast cancer. After an initial delay in the tumor onset, SIRT6-OE induces a more aggressive phenotype of Delta16HER2 tumors promoting the formation of higher number of tumor foci and metastases than controls. This phenotype of SIRT6-OE tumors is associated with cancer stem cell (CSC)-like features and tumor dormancy, and low senescence and oxidative DNA damage. Accordingly, a sub-set of HER2-positive breast cancer patients with concurrent SIRT6-OE has a significant poorer relapse-free survival (RFS) probability than patients with low expression of SIRT6. ChIP-seq, RNA-seq and RT-PCR experiments indicate that SIRT6-OE represses the expression of the T-box transcription factor 3 (Tbx3) by deacetylation of H3K9ac. Accordingly, loss-of-function mutations of TBX3 or low TBX3 expression levels are predictive of poor prognosis in HER2-positive breast cancer patients. Our work indicates that high levels of SIRT6 are indicative of poor prognosis and high risk of metastasis in HER2-positive breast cancer and suggests further investigation of TBX3 as a downstream target of SIRT6 and co-marker of poor-prognosis. Our results point to a breast cancer subtype-specific effect of SIRT6 and warrant future studies dissecting the mechanisms of SIRT6 regulation in different breast cancer subtypes.
    MeSH term(s) Humans ; Animals ; Mice ; Female ; Breast Neoplasms/pathology ; Neoplasm Recurrence, Local ; Sirtuins/metabolism ; Chronic Disease
    Chemical Substances Sirtuins (EC 3.5.1.-) ; SIRT6 protein, human (EC 3.5.1.-)
    Language English
    Publishing date 2023-12-12
    Publishing country England
    Document type Journal Article
    ZDB-ID 2615211-3
    ISSN 2045-2322 ; 2045-2322
    ISSN (online) 2045-2322
    ISSN 2045-2322
    DOI 10.1038/s41598-023-49199-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Walking a Tightrope: A Perspective of Resveratrol Effects on Breast Cancer.

    Bartolacci, Caterina / Andreani, Cristina / Amici, Augusto / Marchini, Cristina

    Current protein & peptide science

    2017  

    Abstract: It is an acknowledged fact that health benefits are derived from fruit- and vegetables-enriched diets. In particular, polyphenols, compounds bearing one or more hydroxyl groups attached to an aromatic ring, are ascribed for most of such beneficial ... ...

    Abstract It is an acknowledged fact that health benefits are derived from fruit- and vegetables-enriched diets. In particular, polyphenols, compounds bearing one or more hydroxyl groups attached to an aromatic ring, are ascribed for most of such beneficial effects. Among them, resveratrol, a phytoalexin found in numerous plant species, and more notably in grapes, has widely piqued the interest of the scientific community by virtue of its anti-aging, anti-inflammatory and anti-oxidant properties. Moreover, evidence claiming resveratrol ability to hinder processes underlying all the three steps of carcinogenesis (tumor initiation, progression and metastasization) has propelled an incredibly massive number of studies aimed at enquiring its eventual clinical potential in the fight against cancer. However, despite a large body of data pointing to the advantages of dietary resveratrol intake in respect of certain disease conditions, and cancer inter alia, its real position still remains quite ambiguous. In this uncertain scenario, the present review focuses its attention on the highly entangled relationship between resveratrol and breast cancer, attempting to shape the plethora of controversial results stemming from studies carried out on several in vitro and in vivo breast cancer models. Coping with such a tricky matter, there are so many variabilities concerning both resveratrol itself (dosage, administration, bioavailabilty, among others) and the unique molecular traits of each specific breast cancer subtype that must be taken into account when facing the dilemma: "might resveratrol be protective against breast cancer or does it rather fuel it?"
    Language English
    Publishing date 2017-01-11
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 2045662-1
    ISSN 1875-5550 ; 1389-2037
    ISSN (online) 1875-5550
    ISSN 1389-2037
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Copper drives remodeling of metabolic state and progression of clear cell renal cell carcinoma.

    Bischoff, Megan E / Shamsaei, Behrouz / Yang, Juechen / Secic, Dina / Vemuri, Bhargav / Reisz, Julie A / D'Alessandro, Angelo / Bartolacci, Caterina / Adamczak, Rafal / Schmidt, Lucas / Wang, Jiang / Martines, Amelia / Biesiada, Jacek / Vest, Katherine E / Scaglioni, Pier P / Plas, David R / Patra, Krushna C / Gulati, Shuchi / Figueroa, Julio A Landero /
    Meller, Jarek / Cunningham, J Tom / Czyzyk-Krzeska, Maria F

    bioRxiv : the preprint server for biology

    2024  

    Abstract: Copper (Cu) is an essential trace element required for mitochondrial respiration. Late-stage clear cell renal cell carcinoma (ccRCC) accumulates Cu and allocates it to mitochondrial cytochrome c oxidase. We show that Cu drives coordinated metabolic ... ...

    Abstract Copper (Cu) is an essential trace element required for mitochondrial respiration. Late-stage clear cell renal cell carcinoma (ccRCC) accumulates Cu and allocates it to mitochondrial cytochrome c oxidase. We show that Cu drives coordinated metabolic remodeling of bioenergy, biosynthesis and redox homeostasis, promoting tumor growth and progression of ccRCC. Specifically, Cu induces TCA cycle-dependent oxidation of glucose and its utilization for glutathione biosynthesis to protect against H
    Language English
    Publishing date 2024-01-19
    Publishing country United States
    Document type Preprint
    DOI 10.1101/2024.01.16.575895
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: HER2-Displaying M13 Bacteriophages induce Therapeutic Immunity against Breast Cancer.

    Wang, Junbiao / Lamolinara, Alessia / Conti, Laura / Giangrossi, Mara / Cui, Lishan / Morelli, Maria Beatrice / Amantini, Consuelo / Falconi, Maurizio / Bartolacci, Caterina / Andreani, Cristina / Orlando, Fiorenza / Provinciali, Mauro / Del Pizzo, Francesco Domenico / Russo, Francesca / Belletti, Barbara / Riccardo, Federica / Bolli, Elisabetta / Quaglino, Elena / Cavallo, Federica /
    Amici, Augusto / Iezzi, Manuela / Marchini, Cristina

    Cancers

    2022  Volume 14, Issue 16

    Abstract: The advent of trastuzumab has significantly improved the prognosis of HER2-positive (HER2+) breast cancer patients; nevertheless, drug resistance limits its clinical benefit. Anti-HER2 active immunotherapy represents an attractive alternative strategy, ... ...

    Abstract The advent of trastuzumab has significantly improved the prognosis of HER2-positive (HER2+) breast cancer patients; nevertheless, drug resistance limits its clinical benefit. Anti-HER2 active immunotherapy represents an attractive alternative strategy, but effective immunization needs to overcome the patient's immune tolerance against the self-HER2. Phage display technology, taking advantage of phage intrinsic immunogenicity, permits one to generate effective cancer vaccines able to break immune tolerance to self-antigens. In this study, we demonstrate that both preventive and therapeutic vaccination with M13 bacteriophages, displaying the extracellular (EC) and transmembrane (TM) domains of human HER2 or its Δ16HER2 splice variant on their surface (ECTM and Δ16ECTM phages), delayed mammary tumor onset and reduced tumor growth rate and multiplicity in ∆16HER2 transgenic mice, which are tolerant to human ∆16HER2. This antitumor protection correlated with anti-HER2 antibody production. The molecular mechanisms underlying the anticancer effect of vaccine-elicited anti-HER2 antibodies were analyzed in vitro against BT-474 human breast cancer cells, sensitive or resistant to trastuzumab. Immunoglobulins (IgG) purified from immune sera reduced cell viability mainly by impairing ERK phosphorylation and reactivating retinoblastoma protein function in both trastuzumab-sensitive and -resistant BT-474 cells. In conclusion, we demonstrated that phage-based HER2 vaccines impair mammary cancer onset and progression, opening new perspectives for HER2+ breast cancer treatment.
    Language English
    Publishing date 2022-08-22
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers14164054
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Author Correction: Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer.

    Bartolacci, Caterina / Andreani, Cristina / Vale, Gonçalo / Berto, Stefano / Melegari, Margherita / Crouch, Anna Colleen / Baluya, Dodge L / Kemble, George / Hodges, Kurt / Starrett, Jacqueline / Politi, Katerina / Starnes, Sandra L / Lorenzini, Daniele / Raso, Maria Gabriela / Solis Soto, Luisa M / Behrens, Carmen / Kadara, Humam / Gao, Boning / Wistuba, Ignacio I /
    Minna, John D / McDonald, Jeffrey G / Scaglioni, Pier Paolo

    Nature communications

    2022  Volume 13, Issue 1, Page(s) 4640

    Language English
    Publishing date 2022-08-08
    Publishing country England
    Document type Published Erratum
    ZDB-ID 2553671-0
    ISSN 2041-1723 ; 2041-1723
    ISSN (online) 2041-1723
    ISSN 2041-1723
    DOI 10.1038/s41467-022-32459-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer.

    Bartolacci, Caterina / Andreani, Cristina / Vale, Gonçalo / Berto, Stefano / Melegari, Margherita / Crouch, Anna Colleen / Baluya, Dodge L / Kemble, George / Hodges, Kurt / Starrett, Jacqueline / Politi, Katerina / Starnes, Sandra L / Lorenzini, Daniele / Raso, Maria Gabriela / Solis Soto, Luisa M / Behrens, Carmen / Kadara, Humam / Gao, Boning / Wistuba, Ignacio I /
    Minna, John D / McDonald, Jeffrey G / Scaglioni, Pier Paolo

    Nature communications

    2022  Volume 13, Issue 1, Page(s) 4327

    Abstract: Mutant KRAS (KM), the most common oncogene in lung cancer (LC), regulates fatty acid (FA) metabolism. However, the role of FA in LC tumorigenesis is still not sufficiently characterized. Here, we show that KMLC has a specific lipid profile, with high ... ...

    Abstract Mutant KRAS (KM), the most common oncogene in lung cancer (LC), regulates fatty acid (FA) metabolism. However, the role of FA in LC tumorigenesis is still not sufficiently characterized. Here, we show that KMLC has a specific lipid profile, with high triacylglycerides and phosphatidylcholines (PC). We demonstrate that FASN, the rate-limiting enzyme in FA synthesis, while being dispensable in EGFR-mutant or wild-type KRAS LC, is required for the viability of KMLC cells. Integrating lipidomic, transcriptomic and functional analyses, we demonstrate that FASN provides saturated and monounsaturated FA to the Lands cycle, the process remodeling oxidized phospholipids, such as PC. Accordingly, blocking either FASN or the Lands cycle in KMLC, promotes ferroptosis, a reactive oxygen species (ROS)- and iron-dependent cell death, characterized by the intracellular accumulation of oxidation-prone PC. Our work indicates that KM dictates a dependency on newly synthesized FA to escape ferroptosis, establishing a targetable vulnerability in KMLC.
    MeSH term(s) Ferroptosis/genetics ; Humans ; Lipid Metabolism/genetics ; Lipogenesis/genetics ; Lung Neoplasms/genetics ; Lung Neoplasms/metabolism ; Phosphatidylcholines ; Proto-Oncogene Proteins p21(ras)/genetics ; Proto-Oncogene Proteins p21(ras)/metabolism
    Chemical Substances KRAS protein, human ; Phosphatidylcholines ; Proto-Oncogene Proteins p21(ras) (EC 3.6.5.2)
    Language English
    Publishing date 2022-07-26
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 2553671-0
    ISSN 2041-1723 ; 2041-1723
    ISSN (online) 2041-1723
    ISSN 2041-1723
    DOI 10.1038/s41467-022-31963-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Resveratrol fuels HER2 and ERα-positive breast cancer behaving as proteasome inhibitor.

    Andreani, Cristina / Bartolacci, Caterina / Wijnant, Kathleen / Crinelli, Rita / Bianchi, Marzia / Magnani, Mauro / Hysi, Albana / Iezzi, Manuela / Amici, Augusto / Marchini, Cristina

    Aging

    2017  Volume 9, Issue 2, Page(s) 508–523

    Abstract: The phytoestrogen resveratrol has been reported to possess cancer chemo-preventive activity on the basis of its effects on tumor cell lines and xenograft or carcinogen- ... ...

    Abstract The phytoestrogen resveratrol has been reported to possess cancer chemo-preventive activity on the basis of its effects on tumor cell lines and xenograft or carcinogen-inducible
    MeSH term(s) Animals ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Down-Regulation/drug effects ; Estrogen Receptor alpha/genetics ; Estrogen Receptor alpha/metabolism ; Female ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Mammary Neoplasms, Experimental/genetics ; Mammary Neoplasms, Experimental/metabolism ; Mammary Neoplasms, Experimental/pathology ; Proteasome Inhibitors/pharmacology ; Receptor, ErbB-2/genetics ; Receptor, ErbB-2/metabolism ; Resveratrol ; Signal Transduction/drug effects ; Stilbenes/pharmacology ; Up-Regulation/drug effects
    Chemical Substances Estrogen Receptor alpha ; Proteasome Inhibitors ; Stilbenes ; Erbb2 protein, mouse (EC 2.7.10.1) ; Receptor, ErbB-2 (EC 2.7.10.1) ; Resveratrol (Q369O8926L)
    Language English
    Publishing date 2017-04-06
    Publishing country United States
    Document type Journal Article
    ISSN 1945-4589
    ISSN (online) 1945-4589
    DOI 10.18632/aging.101175
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Phage-Based Anti-HER2 Vaccination Can Circumvent Immune Tolerance against Breast Cancer.

    Bartolacci, Caterina / Andreani, Cristina / Curcio, Claudia / Occhipinti, Sergio / Massaccesi, Luca / Giovarelli, Mirella / Galeazzi, Roberta / Iezzi, Manuela / Tilio, Martina / Gambini, Valentina / Wang, Junbiao / Marchini, Cristina / Amici, Augusto

    Cancer immunology research

    2018  Volume 6, Issue 12, Page(s) 1486–1498

    Abstract: Δ16HER2 is a splice variant of HER2 and defined as the transforming isoform in HER2-positive breast cancer. It has been shown that Δ16HER2 promotes breast cancer aggressiveness and drug resistance. In the present work, we ... ...

    Abstract Δ16HER2 is a splice variant of HER2 and defined as the transforming isoform in HER2-positive breast cancer. It has been shown that Δ16HER2 promotes breast cancer aggressiveness and drug resistance. In the present work, we used
    MeSH term(s) Animals ; Bacteriophage M13/genetics ; Breast Neoplasms/immunology ; Cancer Vaccines/immunology ; Cancer Vaccines/pharmacology ; Dendritic Cells ; Epitopes/genetics ; Exons ; Female ; Humans ; Immune Tolerance/physiology ; Immunotherapy, Adoptive/methods ; Mice, Inbred Strains ; Mice, Transgenic ; Receptor, ErbB-2/chemistry ; Receptor, ErbB-2/genetics ; Receptor, ErbB-2/immunology ; Vaccines, DNA/immunology
    Chemical Substances Cancer Vaccines ; Epitopes ; Vaccines, DNA ; ERBB2 protein, human (EC 2.7.10.1) ; Receptor, ErbB-2 (EC 2.7.10.1)
    Language English
    Publishing date 2018-10-16
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2732489-8
    ISSN 2326-6074 ; 2326-6066
    ISSN (online) 2326-6074
    ISSN 2326-6066
    DOI 10.1158/2326-6066.CIR-18-0179
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top